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Abstract
Background: The metabolic inhibitor 3-bromopyruvate (3-BrPA) is a promising anti-cancer alkylating agent, shown
to inhibit growth of some colorectal carcinoma with KRAS mutation. Recently, we demonstrated increased
resistance to 3-BrPA in wt p53 tumor cells compared to those with p53 silencing or mutation. Since hypoxic
microenvironments select for tumor cells with diminished therapeutic response, we investigated whether
hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant
NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung
carcinoma with a KRAS (G12S)-mutation. Since hypoxia increases the toxicity of the p53 activator, Prima-1
against breast cancer cells irrespective of their p53 status, we also investigated whether Prima-1 reversed
hypoxic resistance to 3-BrPA.
Results: In contrast to the high susceptibility of hypoxic mutant NRAS MelJuso cells to 3-BrPA or Prima-1,
KRAS mutant C8161 and A549 cells revealed hypoxic resistance to 3-BrPA counteracted by Prima-1. In A549
cells, Prima-1 increased p21CDKN1mRNA, and reciprocally inhibited mRNA expression of the SLC2A1-GLUT1
glucose transporter-1 and ALDH1A1, gene linked to detoxification and stem cell properties. 3-BrPA lowered
CAIX and VEGF mRNA expression. Death from joint Prima-1 and 3-BrPA treatment in KRAS mutant A549 and
C8161 cells seemed mediated by potentiating oxidative stress, since it was antagonized by the anti-oxidant
and glutathione precursor N-acetylcysteine.
Conclusions: This report is the first to show that Prima-1 kills hypoxic wt p53 KRAS-mutant cells resistant to
3-BrPA, partly by decreasing GLUT-1 expression and exacerbating pro-oxidant stress.
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Background
Tumor progression includes clonal selection of cells with
mutated RAS or an inactive p53 tumor suppressor gene,
leading to increased survival within the hypoxic tumor
microenvironment. Aberrant signaling pathways induced
by oncogenic KRAS mutations may help inactivate the
functionality of the p53 tumor suppressor gene through
critical effectors of oncogenic KRAS like Snail [1], Notch1
[2] or Ral GTPases [3]. Down-regulation of KRAS, RalB,
and RalA increases p53 protein levels and results in a p53-
dependent up-regulation of the expression of p21CDKN1A
[3]. Prima-1 (2,2-bis(hydroxymethyl)-1-azabicyclooctan-3-
one) like Prima-1 Met/APR-246, belongs to a group of non-
genotoxic small molecules that promote mutant p53
reactivation and significant growth inhibition in several hu-
man tumor cells [4–9]. More recently, these drugs were re-
ported to activate wild-type p53 and induce apoptosis in wt
p53 malignant melanoma tumors [7], and in hypoxic wt
p53 breast cancer cells [8]. Prima-1Met also has been shown
to induce apoptosis in multiple myeloma [9], Ewing sar-
coma irrespective of p53 status [10], in human prostate
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cancer, in a mouse leukemia cell line lacking p53 expression
[11] and even in tumor cells lacking p53 through inhibition
of thioredoxin reductase I [12]. A common mechanism to
explain the loose dependence on p53 in the response to
Prima-1 or Prima-1Met could be that they take advantage of
the high levels of oxidative stress common to tumor cells
harbouring mutant p53 [8, 13] or oncogenic KRAS [14].
Supporting a role of oxidative stress in p53 reactivation,
normoxic wt p53 breast cancer cells [8] and multiple mye-
lomas [9] increase their susceptibility to Prima-1 with
agents that impair the GSH/ROS balance like the glutathi-
one antagonist, buthionine sulfoximine, which antagonizes
cellular anti-oxidant defence [8, 9]. Reactive oxygen species
(ROS) are also a byproduct of metabolism, being produced
during electron transfer by high metabolic consumption in
tumor cells with moderate ROS levels driving metabolic
processes but high ROS promoting cell death [13, 14].
Oncogenic KRAS mutations increase ROS levels [14] and
overexpression of GLUT1 in lung carcinomas [15]. This
glucose receptor 1 (SLC2A1-GLUT1) transports glucose
which has a role in antioxidant defense [16], since it is the
first substrate in the pentose phosphate pathway generating
NADPH, capable of donating electrons to antioxidant
pathways to attenuate excessive oxidative stress [14–16].
Agents having anti-oxidant properties like pyruvate or N-
acetylcysteine also counteract death by glucose depletion in
human tumor cells [17]. Detoxification of stress caused by
reactive lipid peroxidation can be helped by ALDH1A1 (EC
1.2.1.36) a putative cancer stem cell marker [18] belonging
to a superfamily of NAD(P)+-dependent enzymes that
catalyze the oxidation of a wide variety of endogenous and
exogenous aldehydes to their corresponding carboxylic
acids [18, 19]. ALDH1A1 has prognostic significance in
non-small cell lung cancer [19]. In tumor progression, can-
cer cells adapt to hypoxic stress by inducing expression of
genes coding for carbonic anhydrase IX (CAIX) [20–22] or
vascular endothelial growth factor (VEGF) [23], which also
are important targets in cancer therapy. As a redox-active
transcription factor, the p53 protein core DNA-binding
domain when in contact with DNA, can sense oxidative
stress. When cells are exposed to Prima-1 or to Prima-
1(MET), these molecules yield several active products
among them methylene quinuclidinone (MQ), that reacts
covalently to alkylate p53 cysteine residues and reactivate
p53 function [6]. Moreover, MQ can also target cells irre-
spective of p53 by inhibiting thioredoxin reductase I and
converting it to a pro-oxidant NADPH oxidase to further
increase oxidative stress [6, 12]. Another potent pro-
oxidant is 3-bromopyruvate (3-BrPA), a metabolic competi-
tor of pyruvate [17], and an alkylating agent capable of
depleting ATP and increasing metabolic stress by generating
free radicals [24, 25]. 3-BrPA preferentially suppressed the
growth of some colorectal carcinoma cells with KRAS or
BRAF mutations which survived glucose starvation [26].
Since hypoxia [8] and some RAS mutations [26] may in-
crease drug resistance partly by favouring p53 tumor sup-
pressor dysfunction [8], this report investigated whether
hypoxia unequally induces resistance to 3-BrPA in wt p53
tumor cells like MelJuso melanoma harbouring (Q61L)-
mutant NRAS and wt BRAF, C8161 melanoma with
(G12D)-mutant KRAS (G464E)-mutant BRAF and A549
lung carcinoma with a KRAS (G12S)-mutation. We
also investigated whether the p53 reactivator, Prima-1
counteracts a possible hypoxic resistance to 3-BrPA.
The rationale for studying Prima-1, which alkylates
critical p53 thiol groups [6, 27] together with 3-BrPA,
which alkylates key thiol groups in glycolytic and
mitochondrial targets [24, 25], is because of their pos-
sible synergism to increase ROS [25, 26] and prevent
proliferation and expression of genes associated with
hypoxia and/or glycolysis in cells harbouring mutant




a) MelJuso cells are wt BRAF and mutated in NRAS-
Q61L [28].
b) C8161 cells were initially reported to be wild-type
for both N-RAS and BRAF (http://www.wistar.org/
lab/meenhard-herlyn-dvm-dsc/page/mapk-and-pi3k-
pathways) with greater resistance to MEK inhibition
in three-dimensional culture [29]. Quite recently,
these cells were identified as having a G464E muta-
tion in the BRAF P loop region, accompanied by an
enhancing KRAS G12D mutation [30].
Non-small cell lung cancer cells
c) The A549 human lung adenocarcinoma cell line
(www.atcc.org/~/ps/CRM-CCL-185.ashx) is being
used as an in vitro model for non-small cell lung
cancer (NSCL) harbouring a wt p53 gene and a
KRAS gene mutation (p.G12S c.34G > A). These
wt p53 NSCL cells were found to be resistant to
a 24 h treatment with 100 μM Prima-1 under
normoxia [31].
Cell culture conditions and treatments under high
glucose or physiological glucose
Sparse cells were allowed to attach to tissue-culture dishes
for 20 h in high serum- glucose medium consisting of
Dulbecco’s Modified Medium (DME) Sigma Cat # D1152
containing 4.5 g/lL glucose (∼23 mM) supplemented with
4 mM glutamine and 10% fetal calf serum. Treatments
were added in this higher glucose medium for the indi-
cated times. For studies in the low glucose medium,
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adherent cells seeded for 20 h in high serum- glucose
medium were washed 3 times in isotonic phosphate-
buffered saline pH 7.3, followed by addition of Dulbecco’s
Modified Eagle’s Medium Sigma Cat # D5030, 5 mM
physiological glucose, 2 mM glutamine and 5% dialyzed
calf serum, together with other conditions indicated in
each experiment [17]. Water-soluble reagents like Prima-
1(Sigma #P0069) and/or 3-BrPA (Sigma Aldrich #238341)
were freshly prepared [25], and added whenever indicated.
Unequal time duration of experiments were chosen to
harvest and analyze cells at different times, depending on
whether earlier changes in RNA and protein, cell cycle
events or overt cytotoxicity were studied.
Hypoxia experiments
These were carried out in a hypoxic C-474 chamber
equipped with Pro-Ox 110 oxygen controlling regulators
(Biospherix, New York, N.Y.) to provide (≤2% oxygen).
Relative cell viability/metabolic activity
This was estimated with Alamar Blue (resazurin) by
measuring intracellular redox mitochondrial activity by
quantitating the cell-catalyzed conversion of non-
fluorescent resazurin to fluorescent resorufin [8]. Alamar
Blue was added to a 10% final concentration to each one
of 96 well plates after the appropriate treatment. This
assay is valuable as an endpoint of proliferation or rela-
tive viability/metabolic activity. For these experiments,
cells (5,000) were allowed to adhere overnight in 96 well
TC plates. After the corresponding treatments, Alamar
Blue (BioSource, Camarillo, CA, USA) was added without
removing medium containing dead cells, and fluorescence
measured 4 h later in a Fluoroskan Ascent microplate
reader with an excitation of 544 nm and an emission of
590 nm. Standard deviations (S.D.) were used to determine
a statistically significant difference in the octuplicate me-
dian values shown for metabolic activity/cell viability. Gen-
erally, S.D. results usually were within ±5% with a 95%
statistical significance (n = 4). The criterion for statistical
significance was taken as p < 0.05 by student t test, when-
ever indicated by *.
High content cell cycle analysis by fluorescent imaging
This was carried out using the Cell Cycle Bio-
Application algorithm provided with the Cellomics
Arrayscan VTI at a magnification of 10X, used to iden-
tify objects by nuclear staining with Hoechst dye. A
minimum of 500 individual cellular images or 20 fields
were captured for each condition. The algorithm mea-
sured total nuclear intensity and selected for below 2n
(subG1 dead cells), 2n (G1 cells), 2n-4n (S phase cells), 4
n (G2 cells) and above 4n DNA (multiplody or hyperte-
traploid cells) [32]. Generally, S.D. results usually were
within ±5%.
Intracellular ROS Quantitation
ROS intracellular generation was assayed in adherent
A549 cells seeded in 96 well plates after 9 h of ex-
posure to the indicated treatments in medium supple-
mented with 5 mM glucose. This was quantitated
adding DCFH-DA (Life Technologies), a cell perme-
able non-fluorescent compound that can be hydro-
lyzed by intracellular esterases to DCFH, which
fluoresces green when oxidized by H2O2. Cells were
exposed for 30 min to 20 μM DCFH-DA and 20 μM
LavaCell (Active Motif. Carlsbad, California 92008,
USA) a cell-permeable, non-toxic compound that
stains membranes of live cells orange-red emission
(560-580 nM) for 30 min. Cell-associated fluorescence
was determined in octuplicates, using the signal
thresholding algorithms to identify fluorescence above
the solution background from which fluorescent cells
are identified in an Isocyte argon laser spectrofluo-
rometer (Blueshift Biotechnologies, Inc., Sunnyvale,
Ca.) identifying ROS in channel 1 green fluorescence
(510–540) normalized to channel 3 orange-red cell
fluorescence (560–580 nm).
Crystal violet staining of surviving cells
Cells were subjected to the treatments indicated in each
experiment. Surviving cells were evidenced following fix-
ation in 90% ethanol and cell staining with 0.5% crystal
violet (Cat # C-3886, Sigma–Aldrich, St. Louis, MO.
63103, USA) in 30% ethanol.
Real-time and end-point RT-PCR
Cells were seeded in 5 cm-well plates (3 × 105 cells per
plate) in complete Dulbecco’s medium containing
20 mM glucose supplemented with 10% serum for 24 h.
Cells were washed 3X with PBS and treated as indicated
in medium supplemented with physiological 5 mM glu-
cose and 5% dialyzed serum for 24 h. RNA extraction
was performed using TRIZOL® (Life Technologies, Cat #
15596–026) and quantification was determined using a
Qubit® 2.0 Fluorometer (Life Technologies, Cat
#Q32866) with a Qubit™ RNA Assay Kit (Life Technolo-
gies, Cat # Q32852). The cDNA was prepared with the
ProtoScript® First Strand cDNA Synthesis Kit (New Eng-
land BioLabs, Cat # E6300S) using oligo dT as a primer.
A GeneAmp® PCR System 9700 ABI machine was used
for end-point PCR, followed by agarose gel electrophor-
esis, to confirm lack of reaction in the absence of tem-
plate, and expected size of PCR products. All
amplification reactions were prepared with Q5® High-
Fidelity PCR Kit (New England BioLabs, Cat # E0555S).
Real Time qPCR was carried out in an Illumina Eco
Real-Time PCR machine, in reactions (10 μL) containing
5 μL KAPA SYBR FAST qPCR Master Mix (Kapa Biosys-
tems), 0.5 μM of each primer pair, 1 μL of cDNA template
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Fig. 1 a 3-BrPA potentiates Prima-1 toxicity against A549 cells in 5 mM glucose. A549 cells (4X103) were seeded in tissue culture 96 well plates in
complete medium containing 20 mM glucose and 10% fetal bovine serum, then washed 3X with PBS and treated as indicated in each case, in
medium supplemented with physiological 5 mM glucose, 2 mM glutamine and 5% dialyzed serum for 48 h. Relative proliferation /toxicity was
assayed fluorometrically in octuplicate by the Alamar Blue method by quantitating the conversion of resazurin to fluorescent resorufin [8]. This
revealed that 50 μM Prima-1 cooperated with 3-BrPA rather than with CHC to suppress A549 cell growth. b Prima-1 decreases SLC2A1-GLUT1 in
A549 cells. Sparse cells were seeded in 5 cm tissue culture plates (5 × 105cells per plate) in complete Dulbecco’s medium containing 20 mM
glucose supplemented with 10% serum for 18 h, then washed 3X with PBS and treated as indicated in each case, in medium supplemented with
physiological 5 mM glucose, 2 mM glutamine and 5% dialyzed serum whenever indicated (+) for 24 h. After RNA extraction with TRIZOL and
quantification in a Qubit® 2.0 Fluorometer, cDNAs were prepared for end-point PCR analysis as indicated under Methods.essentially similar results
were obtained in cells treated with Prima-1 in 5 mM glucose (not shown). Cells treated in parallel with those used for RNA analysis were used for
GLUT1 protein immune blot [40]. c Prima-1 activates p21CDKN1A gene expression in A549 cells in 5 mM glucose. qPCR was used to determine
relative expression of the p21CDK1N1 gene in control and treated cells, after RNA extraction, cDNA preparation and qPCR, as indicated under
Methods. *denotes significance between treated cells relative to controls
Table 1 Primer sequence for SYBR Green RT-qPCR and end point PCR analysis
Gen Name Primer sequence Fw Primer sequence Rv
ACTN 5´- CATGTACGTTGCTATCCAGGC-3´ 5´- CTCCTTAATGTCACGCACGAT-3´
GAPDH 5´- GCACCACCAACTGCTTAGCA-3´ 5´-TGGCAGTGATGGCATGGA-3´
SLC2A1 -GLUT1 5´- CGGGCCAAGAGTGTGCTAAA-3´ 5´- TGACGATACCGGAGCCAATG-3´.
CAIX 5´- ATCCTAGCCCTGGTTTTTGG-3´ 5´- GCTCACACCCCCTTTGGTT-3´
ALDH1A1 5´- CAAGATCCAGGGCCGTACAA-3´ 5´- CAGTGCAGGCCCTATCTTCC-3´
LDHA 5´- ATCTTGACCTACGTGGCTTGGA-3´ 5´- CCATACAGGCACACTGGAATCTC-3´
p21 CDK1N1 5´- GGACCTGGAGACTCTCA-3´ 5´- CCTCCTGGAGAAGATCAG-3´
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(ng) and 1 μL RNAse-DNAse free water. PCR reactions
were subjected to 95 °C for 3 min; followed by 40 cycles at
95 °C for 10 s and 60 °C for 30 s. This was followed by
melting curve analysis. The primers sequences used de-
scribed in Table 1, were obtained from Integrated DNA
Technologies (IDT, Coralville, IA 52241, USA). In all cases,
the expression of each gene was normalized by measuring
the expression of the similarly treated housekeeping gene
coding for actin (ACTN) or for glyceraldehyde-3-
phosphate (GAPDH). All experiments were performed in
triplicate. SigmaPlot 11.0 software was used for the statis-
tics analysis of one-way analysis of variance or one-way
ANOVA (p ≤0.01 or p ≤0.05 significance).
Immunofluorescence staining
Immunofluorescence (IF) staining of cells was performed as
previously described [33]. In brief, cells cultured on 96-well
plates as indicated for each experiment, were washed with
ice-cold PBS and fixed with 4% p-formaldehyde in
phosphate-buffered saline. Cells were permeabilized with
PBS containing 0.3% Triton X-100 and blocked in the same
buffer adding 10 mg/ml bovine serum albumin and 1:1 dilu-
tion of mouse pre-immune serum. Subsequently, cells were
incubated overnight with anti-human FITC-conjugated to
GLUT1 monoclonal antibody MAB1418 clone 202915 di-
luted 1:8. and MAB 293 human VEGF mouse monoclonal
antibody clone 26503, both from R&D (614 McKinley Place
N.E. Minneapolis, MN55413 USA) followed by a 90 min in-
cubation with Alexa Fluor 488-conjugated anti-mouse sec-
ondary antibody (Invitrogen). Examination of green GLUT1
was carried out in separate assays by fluorescence micros-
copy in which DNA containing nuclei were stained violet
with Hoechst 33342. Cells showed no fluorescence after re-
action with a negative control IgG in contrast to the reactiv-
ity seen with the specific monoclonal antibodies used.
Results
Prima-1 lowers SLC2A1-GLUT1 mRNA and protein
expression and cooperates with 3-BrPA to promote
toxicity against normoxic A549 cells
Initially, we analyzed the cell proliferation of A549 cells cul-
tured aerobically in complete medium with 10% fetal bo-
vine serum and 20 mM glucose. Previously, others reported
that A549 cells resisted growth inhibition by 100 μM
Prima-1 under normoxic conditions [31]. Now, we ob-
served a limited response of A549 cells to 50 μM Prima-1
Fig. 2 Prima-1 and 3-BrPA cooperate to increase ROS. ROS intracellular generation was assayed in octuplicates in adherent A549 cells
seeded in 96 well plates 10 h after exposure to the indicated treatments in medium supplemented with 5 mM glucose, 2 mM glutamine
and 5% dialyzed serum. This was quantitated using DCFH-DA (Life Technologies), a cell permeable non-fluorescent compound that can
be hydrolyzed by intracellular esterases to DCFH, which fluoresces green when oxidized by H2O2. Cells were exposed to 20 μM DCFH-DA
together with 20 μM LavaCell (Active Motif. Carlsbad, California 92008, USA) for 30 min. The latter is also a cell-permeable, non-toxic
compound that stains membranes of live cells providing an orange-red emission (560–580 nM). Cell-associated fluorescence was
determined using the signal thresholding algorithms identify fluorescence above the solution background from which fluorescent cells are
identified for calculation of morphological and fluorescent parameters in an Isocyte argon laser spectrofluorometer identifying channel 1
green fluorescence (510–540) normalized to channel 3 orange-red cell fluorescence (560–580 nm). *denotes significance between treated
cells relative to controls
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or 150 μM 3-BrPA after 48 h treatments in physiological
5 mM glucose [7]. However, both agents cooperated to sup-
press A549 cell proliferation. In contrast, 150 μM of the
monocarboxylate transporter inhibitor, alpha-cyano-4-hy-
droxy-cinnamate (CHC) [34] did not increase Prima-1 tox-
icity (Fig. 1a). End-point semi-quantitative PCR and
western blot were carried out with cells treated for shorter
intervals than those used for inhibition of cell proliferation,
since early morphological changes were seen following
Prima-1 treatment (not shown). These experiments re-
vealed a marked inhibition of SLC2A1-GLUT1 mRNA and
diminished GLUT1 protein expression normalized to
GAPDH in A549 cells treated with 50 μM Prima-1 (Fig. 1b).
Essentially similar results were obtained in experiments in
which cells were similarly treated but in the presence of
20 mM glucose (not shown).
p21CDKN1A gene expression is increased by Prima-1 but
not by 3-BrPA in A549 cells
Since Prima-1 is known to be a p53 reactivator [3, 6, 7],
and the cyclin-dependent kinase inhibitor p21CDKN1 is
a p53-activated gene promoting the G1 checkpoint con-
trol [35, 36] we confirmed by qPCR that Prima-1 in-
creased expression of the p21CDKN1A mRNA in 5 mM
or 20 mM glucose in A549 cells. However, this was an-
tagonized by concomitant treatment with 3-BrPA
(Fig. 1c), known to induce cell cycle arrest in S phase
and G2/M [37]. The reciprocal effects of Prima-1 and 3-
BrPA on p21CDKN1A expression may be related to the
fact that they act at different cell cycle positions. It was
of interest that the Prima-1 mediated increase in
p21CDKN1A occurred in normoxia, hypoxia or in the
presence of the hypoxia mimetic CoCl2 (Fig. 1d).
Fig. 3 a NAC counteracts toxicity of Prima-1 and 3-BrPA in hypoxic (G12S)-mutant KRAS-A549 cells. Crystal violet staining of surviving cells was
used to compare the response to a 72 h treatment with Prima-1 or 3-BrPA in A549 cultures under hypoxia in complete Dulbecco’s medium
containing 20 mM glucose, 4 mM glutamine supplemented with 10% serum. b and c Prima-1 and 3-BrPA cooperate to inhibit cell cycle
progression and promote hypoxic cell death is antagonized by NAC. Cell cycle analysis and assay of below_2n dead cells was performed as
indicated under Methods for cells cultured under hypoxia for 48 h in 20 mM glucose, 4 mM glutamine supplemented with 10% serum, or 5 mM
glucose, 2 mM glutamine and 5% dialyzed serum. *denotes significance between treated cells relative to controls
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Prima-1 cooperates with 3-BrPA to increase ROS
Since 3-BrPA antagonized p21CDKN1A mRNA induc-
tion by Prima-1 (Fig. 1c), and 50 μM Prima-1 and
150 μM 3-BrPA cooperated to increase A549 cell inhib-
ition (Fig. 1a) this suggested that induction of
p21CDKN1A was not the major mechanism involved in
the potentiation of toxicity by these agents. Based on re-
ports that single treatment with Prima-1 [6, 8, 10–12] or
with 3-BrPA [24, 25] increased ROS production, we in-
vestigated whether this effect was additive. For this,
ROS production derived from the intracellular esterase pro-
cessing of the cell-permeant 2',7'-dichlorodihydrofluorescein
diacetate (DCFH-DA, Life Technologies, Carlsbad, Ca.) was
quantitated cytofluorometrically, by measuring the normal-
ized mean green fluorescence intensity. This showed that
ROS production was essentially doubled after a 9 h treat-
ment with both of these agents, prior to any evidence of
overt toxicity which required 48 h treatments (Fig. 2). Since
Prima-1 can alkylate p53 thiol groups [6] and 3-BrPA is an-
other alkylating agent capable of increasing metabolic stress
by generating free radicals [24, 25], results in Fig. 2 suggests
that potentiation of oxidative stress is likely to mediate the
synergy between 50 μM Prima-1 and 150 μM 3-BrPA, ra-
ther than only p53 activation.
NAC counteracts toxicity of Prima-1 and 3-BrPA in (G12S)-
mutant KRAS-A549 cells
Based on the results shown in Fig. 2 we used the anti-
oxidant N-acetylcysteine (NAC) to investigate whether NAC
scavenging antagonized the effects of Prima-1 and 3-BrPA.
Crystal violet survival studies revealed that Prima-1 was
toxic as a single agent after 72 h of hypoxia against A549
cells in 20 mM glucose + 4 mM glutamine + 10% serum,
which were not affected by 3-BrPA. However, Prima-1
Fig. 4 a Prima-1 lowers SLC2A1-GLUT1 gene expression in 5 mM glucose. A549 cells exposed to 5 mM glucose, 2 mM glutamine and 5% dialyzed
serum, were kept for 4 h in hypoxia whenever indicated, followed by RNA isolation, and RT-qPCR, to assay SLC2A1-GLUT1 and ACTN gene expression
bv qPCR, as indicated under Methods. b Decrease in ALDH1A1 induced by 3-BrPA is potentiated by Prima-1. Cells treated as indicated above were
exposed to hypoxia whenever indicated, followed by RNA isolation, and RT-qPCR, to assay ALDH1A1 and ACTN gene expression bv RT- qPCR.
c 3-BrPA counteracts Prima-1 hypoxic induction of VEGF gene expression. Cells treated as indicated above were exposed to hypoxia whenever
indicated, followed by RNA isolation, and RT-qPCR, to assay VEGF and ACTN gene expression by RT- qPCR. d 3-BrPA suppresses CAIX gene expression.
Cells seeded as indicated above were exposed to hypoxia for 4 h whenever indicated, followed by RNA isolation, and RT-qPCR, to assay CAIX and
ACTN gene expression by q PCR. *denotes significance between treated cells relative to controls. **denotes significance between unequal treatments.
***denotes significance between hypoxia and normoxia
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toxicity against hypoxic A549 cells was counteracted by
NAC even when added together with 3-BrPA (Fig. 3a).
Prima-1 and 3-BrPA cooperation to inhibit cell cycle
progression and promote hypoxic (<2n) cell death is
antagonized by NAC
Cell cycle analysis was used to determine the influence
of glucose supplementation and the consequences of
48 h treatments with Prima-1, 3-BrPA or NAC, under
hypoxia. In 20 mM glucose and 4 mM glutamine,
control cells and those treated with NAC were mostly in S
phase (2n-4n). Cell cycle progression decreased recipro-
cally with an augmentation of the below_2n dead cell
population [32] with single Prima-1 treatment and even
more when this treatment was accompanied by 3-BrPA,
effect reverted by NAC (Fig. 3b). In contrast, in 5 mM glu-
cose, 2 mM glutamine and 5% dialyzed serum, there was
an increase in the below_2n dead cell population when
both Prima-1 and 3-BrPA were added to hypoxic A549
cells (Fig. 3c).
GLUT1 is preferentially decreased by Prima-1 and ALDH1A1
is decreased by Prima-1 or 3-BrPA in 5 mM glucose in A549
cells
We also investigated the contribution of 3-BrPA to the
regulation of GLUT1 and ALDH1A1 in physiological
Fig. 5 Prima-1 and 3-BrPA preferentially decrease hypoxia-induced LDHA rather than GAPDH in A549 cells. RT-qPCR was used to assay the effect
of 3-BrPA and Prima-1 on LDHA and GAPDH gene expression under normoxia or 3 h under hypoxia. Note that combined use of Prima-1 and
3-BrPA lowers hypoxic LDHA expression in about 40%, in contrast to only an approximate 25% decline in hypoxic GAPDH expression by the same
combined treatment. *denotes significance between hypoxic and normoxic cells. **denotes significance between treated and control cells
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5 mM glucose including Prima-1 when indicated. This
revealed the preferential SLC2A1-GLUT1 decrease by
Prima-1, partly attenuated by 3-BrPA particularly under
hypoxia (Fig. 4a). In contrast, 3-BrPA preferentially
down-regulated ALDH1A1 mRNA and this was not
attenuated by Prima-1 (Fig. 4b).
Prima-1 mediated enhancement of CAIX and VEGF under
hypoxia in 5 mM glucose is antagonized by 3-BrPA in
A549 cells
Expression of CAIX and VEGF mRNAs was not lowered
significantly by Prima-1, as evidenced by qPCR. However,
the expression of these 2 hypoxia-induced genes was
diminished by 3-BrPA (Fig. 4c and d).
Prima-1 and 3-BrPA cooperate to preferentially decrease
LDHA rather than GAPDH in hypoxic A549 cells in 5 mM
glucose
Since LDHA [38] and GAPDH [39] are also involved in
glycolysis and hypoxia, their modulation by Prima-1
and/or 3-BrPA was investigated under normoxia or hyp-
oxia in 5 mM glucose. Although mRNA expression of
both genes was increased by hypoxia, Prima-1 and
3-BrPA preferentially cooperated to decrease hypoxia-
induced LDHA rather than hypoxia-induced GAPDH
(Fig. 5a and b).
Prima-1 and 3-BrPA decrease GLUT1 external localization
under hypoxia in A549 cells
Since cell-surface localization of the GLUT1 receptor is
expected to promote glucose uptake [40], immune fluor-
escence localization of GLUT1 was compared in hypoxic
control cells and in those treated with Prima-1, 3-BrPA,
and/or the anti-oxidant N-acetylcysteine NAC, whenever
indicated. This revealed preferential surface fluorescence
essentially in control cells (Fig. 6).
Hypoxic resistance to 3-BrPA in mutant KRAS C8161 cells
is counteracted by Prima-1
The susceptibility to Prima-1, 3-BrPA and NAC in
MelJuso cells (BRAF wild-type (wt) and NRAS-Q61L
mutant) [29] was compared with that of C8161 mel-
anoma with an enhancing KRAS G12D mutation and
a G464E mutation in the BRAF P loop region [31].
Under normoxia, both cell types were highly sucepti-
ble to either 75 μM Prima-1 or 100 μM 3-BrPA.
However, NAC only protected C8161 cells from treat-
ment with Prima-1 and 3-BrPA (Fig. 7a). Under hyp-
oxia, susceptibility to Prima-1 persisted in both cell
types but NRAS-mutant MelJuso cells showed greater
susceptibility to 3-BrPA, compared to C8161 cells.
Another difference between these 2 cell types was
that 2 mM NAC counteracted the toxicity of Prima-1
and 3-BrPA only in hypoxic C8161 cells with no
comparable attenuation against MelJuso cells (Fig. 7b).
Fig. 6 Decreased GLUT1 external localization by Prima-1 and 3-BrPA exposed for 3 h to hypoxia in A549 cells is not reverted by 2 mM NAC.
Inmmune fluorescence was used to analyze preferential cell surface (red arrows) or perinuclear localization (white arrows) in p-formaldehyde fixed
and permeabilized cells, treated as indicated in each case under hypoxia
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The NAC results counteracting the toxicity of Prima-1
and 3-BrPA also imply that this is mediated by oxidative
stress, as shown for A549 cells (Figs. 2 and 3).
Unequal modulation of glycolysis-hypoxia associated
gene expression in MelJuso and C8161 cells
Since 3-BrPA decreased VEGF and CAIX and Prima-1
inhibited SLC2A1-GLUT1 gene in KRAS-mutant A549
cells under hypoxia (Fig. 3), these parameters were also
investigated by RT-qPCR in MelJuso and C8161 cells.
When normalized to actin mRNA levels, control Mel-
Juso cells showed much lower SLC2A1-GLUT1 expres-
sion than C8161 cells under comparable conditions.
Although 3-BrPA increased the SLC2A1-GLUT1 expres-
sion in MelJuso cells, this was attenuated by Prima-1.
Neither 3-BrPA nor Prima-1 lowered significantly
SLC2A1-GLUT1 expression in C8161 cells under
normoxia (not shown). However, SLC2A1-GLUT1
Fig. 7 Resistance to 3-BrPA exposed for 4 h to hypoxia is counteracted by Prima-1 in C8161 cells. 5 x 103 C8161 and MelJuso cells were allowed to
adhere for 18 h in complete Dulbecco’s medium with 20 mM glucose, 4 mM glutamine and 10% fetal bovine serum, and subsequently exposed to
the indicated treatments in the same medium for 72 h, followed by 3 h of hypoxia or normoxia. After washing twice in phosphate buffered saline
pH7.4, adherent cells were fixed in 70% ethanol and surviving cells were evidenced by crystal violet staining a) normoxic cells; b) hypoxic cells
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expression was diminished by 3-BrPA, Prima-1 or
both treatments after 5 h of hypoxia in C8161 cells
(Fig. 8a, b). Although CAIX gene expression was
inhibited by Prima-1 in MelJuso and C8161 cells
(Fig. 9a and b), ALDH1A1 and VEGF gene expression
were inhibited by Prima-1 only in MelJuso cells
(Fig. 9).
Discussion
3-BrPA is a pro-oxidant and alkylating anti-tumor agent
capable of inhibiting glycolytic and mitochondrial targets
and generating free radicals [17, 24, 25]. 3-BrPA at
110 μM was shown to suppress the growth of colorectal
carcinoma cells with KRAS or BRAF mutations surviv-
ing glucose starvation [26]. In contrast, we showed in
aerobic ERα positive breast cancer cells, that wt p53
conferred resistance to 3-BrPA, since p53 silencing, or
use of genetically matched cells with mutant p53 R175H,
revealed high susceptibility to 75 μM 3-BrPA [41]. The
wt p53-induced resistance to 3-BrPA was independently
confirmed in RT4 (grade I; wild-type p53) bladder can-
cer cells that remained unaffected by 125 μM 3-BrPA, in
contrast to T24 (grade III; mutant p53) bladder cancer
cells, which greatly diminished their survival at compar-
able 3-BrPA concentrations [42]. This report further in-
vestigated how to enhance 3-BrPA toxicity against wt
p53 A549 non-small cell lung cancer cells harbouring a
KRAS G12S gene mutation. These A549 cells also
showed poor susceptibility to 3-BrPA (Figs. 1 and 2).
Others previously reported poor susceptibility to
Fig. 8 a SCL2A1-GLUT1 gene expression increased under hypoxia by 3-BrPA is antagonized by Prima-1 in MelJuso cells . RT-qPCR was used to
assay the effect of 3-BrPA and Prima-1 on SLC2A1-GLUT1 normalized to ACTN gene expression under normoxia or 3 h of hypoxia in MelJuso cells,
treated as indicated in Fig. 4a. Note that combined use of Prima-1 and 3-BrPA lowers SLC2A1-GLUT1 expression induced by 3-BrPA after 3 h
hypoxia in MelJuso cells. b 3-BrPA or Prima-1 preferentially decrease hypoxic SCL2A1-GLUT1 gene expression in C8161 cells. RT-qPCR was used to
assay the effect of 3-BrPA and Prima-1 on SLC2A1-GLUT1 normalized to ACTN gene expression under 3 or 5 h of hypoxia in C8161 cells, treated
as indicated in Fig. 4a. Here, Prima-1, 3-BrPA or both treatments lowered SLC2A1-GLUT1 gene expression. *denotes significance between treated
cells relative to controls. ** denotes significance between unequal treatments. ***denotes significance between 3 h and 5 h hypoxia
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100 μM Prima-1 in aerobic A549 cells in RPMI 1640
medium containing 11 mM glucose plus any sugar con-
tained in non-dialyzed 10% fetal bovine serum [31].
Since basal oxidative stress is increased by mutant p53
[13] or mutant KRAS [14], and can be further exacer-
bated by 3-BrPA [25] or Prima-1 [12], we showed for the
first time that the latter 2 agents cooperate to hyper-
induce ROS under aerobic conditions (Fig. 2) and coun-
teract hypoxic resistance to 3-BrPA using physiological
5 mM glucose levels. Although KRAS mutant cells over-
express glucose transporter-1 (SLC2A1-GLUT1) [14]
with some of the glucose directed to attenuate excessive
oxidative stress through the generation of NADPH by
the pentose phosphate pathway [14–16], we showed that
Prima-1 decreased GLUT-1 expression in A549 cells
(Fig. 1b) and in C8161 cells (Fig. 5c), result compatible
with that of other p53-reactivating molecules [43].
Moreover, 50 μM Prima-1 also synergized with 150 μM
3-BrPA rather than with 150 μM CHC to inhibit A549
aerobic cell proliferation (Fig. 1a). Under hypoxia, A549
cells were also resistant to 150 μM 3-BrPA but suscep-
tible to 75 μM Prima-1, when used as single agents
(Fig. 3a). The toxicity caused by Prima-1 + 3-BrPA under
hypoxia involved excessive ROS, since it was reversed by
the glutathione precursor, NAC (Fig. 3a). The 72 h crys-
tal violet assay after hypoxic treatment with 75 μM
Prima-1 (Fig. 3a) is compatible with reports of Prima-1
anti-tumor activity under hypoxia irrespective of p53
status [8, 11]. A cytofluorometric cell cycle analysis [32]
after a shorter 48 h hypoxic treatment confirmed that
Prima-1 was more effective than 3-BrPA as a single
agent against KRAS-mutant A549 but also showed that
Fig. 9 Modulation of CAIX, ALDH1A1 and VEGF mRNA expression by Prima-1 ± 3-BrPA. Cells cultured as indicated in Fig. 4a was used for RT-qPCR
to assay the effect of 3-BrPA and Prima-1 on CAIX, ALDH1A1 and VEGF normalized to ACTN gene expression under normoxia or 3 h of hypoxia:
a and b Hypoxia –induced CAIX gene expression is inhibited by Prima-1 in MelJuso and C8161 cells. c and d ALDH1A1 gene expression is preferentially
inhibited by Prima-1 irrespective of 3-BrPA in MelJuso cells compared to C8161 cells. e and f VEGF gene expression is preferentially inhibited by Prima-1
in MelJuso cells compared to C8161 cells. *denotes significance between treated cells relative to controls. **denotes significance between unequal
treatments. ***denotes significance between hypoxia and normoxia
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3-BrPA cooperated to inhibit cell cycle progression and
promote (<2n) cell death antagonized by NAC in these
cells (Fig. 3b and c). NAC prevented Prima-1 ± 3-BrPA
toxicity against hypoxic KRAS G12S-mutant A549 cells
(Fig. 3) and KRAS G12D-mutant C8161 cells (Fig. 7). In
contrast, hypoxic NRAS-(Q61L)-mutant MelJuso melan-
oma cells were greatly susceptible to 3-BrPA or Prima-1,
but were not protected by NAC (Fig. 7b). Unequal re-
sponse to NAC may be linked to lower endogenous anti-
oxidant glutathione in hypoxic NRAS-(Q61L)-mutant
MelJuso susceptible cells, and lower basal SCL2A1-
GLUT1 mRNA expression normalized to actin mRNA,
compared to that seen in the 3-BrPA resistance in hyp-
oxic C8161 cells (Fig. 8). In our studies, cells were
seeded in complete Dulbecco’s medium containing
20 mM glucose supplemented with undialyzed 10%
serum for 24 h. followed by washing 3X with PBS and
treated as indicated in each case in medium supple-
mented with physiological 5 mM glucose and 5% dia-
lyzed serum. The transition from 20 to 5 mM glucose
together with a hypoxic (≤ 2% oxygen) possibly mim-
icked a restrictive glucose condition [44]. The latter af-
fects inducibility of HIF-1α and some of the genes
induced by hypoxia, which requires not only low oxygen
but significant glucose availability [44–47]. This may ex-
plain the lower VEGF expression in 5 mM glucose in
hypoxic A549 (Fig. 4c) and MelJuso cells (Fig. 9e), re-
sembling results showing lower VEGF-A transcripts in
mouse pancreas beta cells after hypoglycemia [48] No
comparable decrease was seen in VEGF or CAIX mRNA
expression in hypoxic C8161 cells (Fig. 9f ), implying
that the response to hypoxia in 5 mM glucose may
be tumor cell-dependent. A similar glucose concentra-
tion also enhanced 3-BrPa-induced cell death in
colorectal carcinoma Lovo and HT-29 cells, which
was suppressed at 20 mM glucose, concomitantly with
down-regulation of the hMCT1 bromopyruvate carrier
[44]. Our findings that hypoxia increases resistance to
3-BrPA in KRAS-mutant wt p53 tumor cells rather
than in those with NRAS mutation, and the reversal
of this resistance with Prima-1 is important, because
no effective single clinical therapy has been
consistently achieved to treat tumors linked to KRAS
[28, 37, 38] or NRAS mutations [28, 40, 49–51]. The
greater susceptibility to Prima-1 ± 3-BrPA in hypoxic
mutant NRAS MelJuso melanoma (Summary, Fig. 10),
suggests that agents like Prima-1 + 3-BrPA, may help
attenuate the frequent acquisition of resistance to
Fig. 10 SUMMARY NRAS. NRAS-mutant cell hypoxic susceptibility to Prima-1 ± 3-BrPA is not reversed by 2 mM NAC. Hypoxic resistance of KRAS
mutant cells to 3-BrPA correlates with greater attenuation of Prima-1 toxicity by 2 mM NAC
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targeted therapy against V600E BRAF-mutated tumors
which acquire NRAS mutations [52].
Conclusions
This report compared tumor cells with KRAS or NRAS
mutations, because those with HRAS constitute only 1–
3% of human cancers [53], with KRAS or NRAS muta-
tions being more frequent. Mutated KRAS induces
GLUT1 [26, 39] and stem cell-like properties in human
cancer [54] linked to ALDH1A1 expression [18, 19].
Prima-1 by itself or in combination with 3-BrPA down-
regulates these genes and also lowers CAIX [20, 21] and
VEGF mRNA expression [55]. Addressing the question
of toxicity of this combination treatment on normal
cells, Prima-1 analog PRIMA-1Met shows limited cyto-
toxicity toward normal hematopoietic cells while de-
creasing multiple myeloma cell viability irrespective of
p53 status [56]. Similarly, 3-BrPA does not affect non-
malignant cells [57] being incorporated into glycolytic
tumor cells through the monocarboxylate transporter
hMCT1 [58] known to be down-regulated by high glu-
cose [44]. Hence, resistance of hypoxic KRAS-mutant
tumor cells to 3-BrPA through lower hMCT1 is likely
to be antagonized by lower glucose uptake linked to di-
minished GLUT-1 transporter expression, a p53 func-
tion [59] now shown to be reactivated by Prima-1.
Taken together, this is the first report showing that
Prima-1 overcomes the resistance to 3-BrPA in hypoxic
wt p53 KRAS-mutant cells [8, 28, 33, 60] by promoting
wt p53 reactivation [61] and pro-oxidant cancer thera-
peutics [9, 12, 62].
Highlights
 Hypoxia increases resistance to 3-bromopyruvate
(3-BrPA) in KRAS-mutant wt p53 cells
 Prima-1, a p53 reactivator decreases GLUT1 and
counteracts hypoxic resistance to 3-BrPA
 N-acetylcysteine reverts toxicity induced by Prima-1
and 3-BrPA
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